HTB

2019

Introduction to ART – October 2019

UK Guide to PrEP – November 2019

i-Base 2019 appeal: we need your help….

17th European AIDS Conference (EACS 2019)

Capsid inhibitor GS-6207 (lenacapavir): potential for 6 monthly dosing for MDR HIV

Dolutegravir/lamivudine as dual ART

Weight changes with doravirine-based first line therapy

Bone and renal changes in the ADVANCE trial

10th International Workshop on HIV and Ageing

Featured Impact of isolation and loneliness on older people living with HIV

Doravirine approved by NHS England as single NNRTI and as part of FDC with 3TC/TDF

Fostemsavir submitted to US FDA for multidrug resistant HIV

Paediatric dispersible formulation of dolutegravir submitted to EMA and FDA

Tesamorelin for NAFLD in people living with HIV

13 December 2019 vol 20 no 14

HTB 13 December 2019 online

Where is cell and gene therapy in an HIV cure?

HTB 15 November 2019 online

17th European AIDS Conference (EACS 2019)

EACS launch major update to European Treatment Guidelines (November 2019)

Weight gain and metabolic syndrome with dolutegravir and TAF: results from the ADVANCE trial

10th International Workshop on HIV and Ageing

Frailty in HIV care and the importance of lifestyle changes

Research into use of medicinal cannabis in HIV management

Vaping can help HIV positive smokers who are not motivated to quit cigarettes

Ibalizumab approved in the EU

US government claims patent infringement by Gilead Sciences over use of F/TAF and FTC/TDF as PrEP

Distinguishing potential mechanisms of HIV persistence

Case report from the first clinical trial of CRISPR-edited stem cells in people with HIV and cancers

DR-TB drugs under the microscope: five urgent actions to improve DR-TB treatment (6th edition)

15 November 2019 vol 20 no 13

HTB 18 October 2019 online

IDWeek (2019), 2–6 October 2019, Washington DC

HIV suppression and safety with ibalizumab at 48 weeks in expanded access

Oral cabotegravir and rilpivirine is durable for 5.5 years in LATTE study

Dolutegravir plus rilpivirine had good virologic, safety record in clinics before single tablet available

Switching from TDF to TAF linked to higher BMI and cardio risk

Possible higher diabetes risk with raltegravir or PIs than NNRTIs

Fostemsavir interaction study flags strong CYP3A inducers, statins, oral contraceptives

Over half of mostly black US HIV group has NAFLD – and many have NASH

People taking more medications and women have higher fall risk in older HIV group

No link between raltegravir and adverse birth outcomes in analysis in 2550 women

PrEP linked to lower HIV incidence in US, independent of TasP

Dual dolutegravir/lamivudine submitted to US FDA as switch option

UK contributes £1.4 billion towards Global Fund for 2020 to 2022

Global Fund raises US$14 billion for 2020 to 2022

NHS England best practice in HIV prescribing and multidisciplinary teams

US approves F/TAF for PrEP (Descovy): indication excludes risk from receptive vaginal sex

Science journal retracts article linking CCR5 deletion to reduced life expectancy

18 October 2019 vol 20 no 12

HTB 30 September 2019 online

10th IAS Conference on HIV Science (IAS 2019): final reports

Low rates of pregnancy with three methods of contraception in the ECHO trial

Scotland approves dual therapy with dolutegravir/lamivudine (Dovato)

FDA expands indication for doravirine in the US as switch option

Greater weight gain with INSTI-based than non-INSTI-based ART among women in US cohort

WHO update PrEP guidelines to include event-based dosing

UK issue joint guidelines on HIV discrimination in tattoo and beauty salons

UK HIV organisations call for urgent review of crisis in sexual health funding

UK is one of four EU countries to lose measles elimination status

Women and HIV research: free educational webcasts

30 September 2019 vol 20 no 11

Other pregnancy studies IAS 2019

HTB 23 August 2019 online: second reports from IAS 2019

10th IAS Conference on HIV Science (IAS 2019) in Mexico City

Post navigation